---
title: "转录组样本量差距巨大，先做 PSM 再分析，靠谱吗？"
date: 2026-01-21T13:37:46Z
draft: ["false"]
tags: [
  "fetched",
  "生信菜鸟团"
]
categories: ["Acdemic"]
---
转录组样本量差距巨大，先做 PSM 再分析，靠谱吗？ by 生信菜鸟团
------
<div><section data-tool="mdnice编辑器" data-website="https://wechat.jeffjade.com/" data-pm-slice="0 0 []"><p data-tool="mdnice编辑器"><span leaf="">在真实世界的肿瘤多组学数据库分析中，“样本量不平衡”几乎是一个不可回避的问题。</span></p><p data-tool="mdnice编辑器"><span leaf="">以 </span><strong><span leaf="">cBioPortal</span></strong><span leaf=""> 为例，其整合了 TCGA、METABRIC 等多个大型癌症队列，整体样本量巨大，但在具体分组分析时，常常出现</span><strong><span leaf="">极端不对称的样本结构</span></strong><span leaf="">，例如：</span></p><ul><li><section><span leaf="">全队列样本数： 大于1000 例</span></section></li><li><section><span leaf="">特定亚群（如某一临床表型）：约 100 例，甚至不足100例。</span></section></li></ul><p data-tool="mdnice编辑器"><span leaf="">这时候直接做差异分析，往往会出现一个尴尬现象：</span></p><blockquote><p><span leaf="">明明生物学上“感觉有差异”， 但统计结果却“不显著”。</span></p></blockquote><p data-tool="mdnice编辑器"><span leaf="">也就是说，如果在不加控制的情况下直接进行差异表达分析或风险因素评估，这种样本量差距极易导致两类问题：</span></p><ul><li><section><strong><span leaf="">假阳性（false positive）</span></strong><span leaf="">：结果更多反映“人群构成差异”，而非研究变量本身；</span></section></li><li><section><strong><span leaf="">假阴性（false negative）</span></strong><span leaf="">：小样本组的真实生物学信号被大样本的噪声所淹没。</span></section></li></ul><p data-tool="mdnice编辑器"><span leaf="">于是，一个看似合理的想法出现了：</span><strong><span leaf="">能不能先用倾向性评分匹配（PSM），再做转录组分析？</span></strong></p><h2 data-tool="mdnice编辑器"><span></span><span><span leaf="">倾向性评分匹配（PSM）</span></span><span></span></h2><p data-tool="mdnice编辑器"><strong><span leaf="">倾向性评分匹配（PSM）</span></strong><span leaf=""> 本质上是一种“类随机化”的统计策略，其核心目标并不是增加样本量，而是：</span></p><blockquote><p><strong><span leaf="">在非随机分组条件下，尽可能平衡两组样本在关键混杂因素上的分布，从而提高因果推断的可信度。</span></strong></p></blockquote><p data-tool="mdnice编辑器"><span leaf="">因此，在样本量悬殊的转录组分析中，PSM 更像是一个“质量控制步骤”，而不是简单的统计技巧。</span></p><h2 data-tool="mdnice编辑器"><span></span><span><span leaf="">一、先说结论：PSM 不能“救样本量”，但能“救可比性”</span></span><span></span></h2><blockquote><p><strong><span leaf="">PSM 不能弥补样本量不足，也不能真正提高统计功效； 但在特定情况下，它可以减少样本异质性，从而间接降低假阴性。</span></strong></p></blockquote><p data-tool="mdnice编辑器"><span leaf="">换句话说：</span></p><ul><li><section><span leaf="">❌ PSM 不是“提高 power 的工具”</span></section></li><li><section><span leaf="">✅ PSM 是“减少混杂、提高组间可比性的方法”</span></section></li></ul><p data-tool="mdnice编辑器"><span leaf="">如果你是想“让 P 值变小”，PSM 一定会让你失望； 如果你是想“让比较更干净”，PSM 可能是有价值的。</span></p><h2 data-tool="mdnice编辑器"><span></span><span><span leaf="">二、PSM 成败的关键：协变量（risk factors）如何选择？</span></span><span></span></h2><p><span leaf=""><span textstyle="">常见的审稿人质疑：Clarification on Propensity Score Matching and Risk Factor Selection: The manuscript employs propensity score matching (PSM) to evaluate certain risk factors, but the rationale for selecting these particular variables remains unclear. Since PSM is sensitive to the quality and relevance of included covariates, it would be helpful to justify the choice of these specific risk factors for adjustment or regulation.</span></span></p><p data-tool="mdnice编辑器"><span leaf="">正如审稿人指出的那样，</span><strong><span leaf="">PSM 对协变量选择高度敏感</span></strong><span leaf="">。 不恰当的变量纳入，可能导致“过度匹配”或“无效匹配”，反而削弱分析效能。</span></p><p data-tool="mdnice编辑器"><span leaf="">审稿人之所以会追问 PSM 变量选择，本质上是在确认三点：</span></p><ol><li><section><strong><span leaf="">这些变量是否在分组之前就已确定？</span></strong></section></li><li><section><strong><span leaf="">它们是否同时影响分组和转录组背景？</span></strong></section></li><li><section><strong><span leaf="">它们是否位于研究假设的因果通路之外？</span></strong></section></li></ol><p data-tool="mdnice编辑器"><span leaf="">用乳腺癌举个例子，如果你的研究目标本身是：</span></p><ul><li><section><span leaf="">ER⁺ vs ER⁻</span></section></li><li><section><span leaf="">HER2⁺ vs HER2⁻</span></section></li><li><section><span leaf="">或激素受体 / HER2 驱动通路机制</span></section></li></ul><p data-tool="mdnice编辑器"><span leaf="">那么把 ER / PR / HER2 纳入 PSM：</span></p><blockquote><p><span leaf="">等同于在设计阶段</span><strong><span leaf="">消除你真正想研究的生物学差异</span></strong><span leaf="">， 这是典型的过度匹配（overmatching）。</span></p></blockquote><p data-tool="mdnice编辑器"><span leaf="">PSM真正做的是：</span></p><ol><li><section><span leaf="">在样本层面，根据协变量估计每个样本“进入某一组的概率”</span></section></li><li><section><span leaf="">在概率相近的样本之间进行匹配</span></section></li><li><section><strong><span leaf="">在匹配后的样本子集中，再进行转录组差异分析</span></strong></section></li></ol><p data-tool="mdnice编辑器"><span leaf="">它的本质是：</span><strong><span leaf="">先让“谁和谁可比”这件事变得更合理，再谈基因差异。</span></strong></p><hr><h2 data-tool="mdnice编辑器"><span></span><span><span leaf="">三、什么情况下，转录组分析“可以考虑”先做 PSM？</span></span><span></span></h2><p data-tool="mdnice编辑器"><span leaf="">可以用下面这张清单自查：</span></p><ul><li><section><span leaf="">两组样本量差距明显（例如 ≥ 3–5 倍）</span></section></li><li><section><span leaf="">大样本组内部高度异质</span></section></li><li><section><span leaf="">存在明确、可量化的混杂因素</span></section></li><ul><li><section><span leaf="">年龄、性别</span></section></li><li><section><span leaf="">肿瘤分期 / 负荷</span></section></li><li><section><span leaf="">RNA 质量（RIN）</span></section></li><li><section><span leaf="">测序深度</span></section></li><li><section><span leaf="">批次信息</span></section></li></ul><li><section><span leaf="">研究目标是</span><strong><span leaf="">机制探索</span></strong><span leaf="">，而不是构建预测模型</span></section></li></ul><p data-tool="mdnice编辑器"><span leaf="">👉 </span><strong><span leaf="">只有在这些条件成立时，PSM 才是“合理选项”，而不是统计投机。</span></strong></p><hr><h2 data-tool="mdnice编辑器"><span></span><span><span leaf="">四、转录组中做 PSM，最容易踩的 3 个坑</span></span><span></span></h2><h3 data-tool="mdnice编辑器"><span></span><span leaf="">❌ 坑 1：把基因表达量拿去算倾向性评分</span><span></span></h3><p data-tool="mdnice编辑器"><span leaf="">包括：</span></p><ul><li><section><span leaf="">目标基因（如 PGBD5、SMAD6）</span></section></li><li><section><span leaf="">PCA 成分</span></section></li><li><section><span leaf="">差异基因</span></section></li><li><section><span leaf="">免疫浸润推断结果</span></section></li></ul><p data-tool="mdnice编辑器"><span leaf="">这是</span><strong><span leaf="">典型的数据泄漏（data leakage）</span></strong><span leaf="">， 在方法学上是站不住脚的。</span></p><hr><h3 data-tool="mdnice编辑器"><span></span><span leaf="">❌ 坑 2：说“PSM 是为了提高统计功效”</span><span></span></h3><p data-tool="mdnice编辑器"><span leaf="">这是</span><strong><span leaf="">审稿人最敏感的一句话</span></strong><span leaf="">。</span></p><p data-tool="mdnice编辑器"><span leaf="">正确说法应该是：</span></p><ul><li><section><span leaf="">“to reduce confounding”</span></section></li><li><section><span leaf="">“to improve comparability”</span></section></li><li><section><span leaf="">“to reduce heterogeneity”</span></section></li></ul><p data-tool="mdnice编辑器"><span leaf="">而不是：</span></p><ul><li><section><span leaf="">“to increase power”</span></section></li><li><section><span leaf="">“to avoid false negatives directly”</span></section></li></ul><hr><h3 data-tool="mdnice编辑器"><span></span><span leaf="">❌ 坑 3：PSM 后样本太少，还硬做差异分析</span><span></span></h3><p data-tool="mdnice编辑器"><span leaf="">PSM 会丢样本，这是必然代价。</span></p><p data-tool="mdnice编辑器"><span leaf="">经验上：</span></p><ul><li><section><span leaf="">匹配后每组 </span><strong><span leaf="">≥ 5–6 个样本</span></strong></section></li><li><section><span leaf="">否则转录组差异分析本身就不稳定</span></section></li></ul><h2 data-tool="mdnice编辑器"><span></span><span><span leaf="">一句话总结</span></span><span></span></h2><p data-tool="mdnice编辑器"><span leaf="">如果你的研究确实存在：</span></p><ul><li><section><span leaf="">样本量严重不平衡</span></section></li><li><section><span leaf="">明确的基线混杂</span></section></li><li><section><span leaf="">机制探索导向</span></section></li></ul><p data-tool="mdnice编辑器"><span leaf="">那么，</span><strong><span leaf="">谨慎、规范地在样本层面引入 PSM，是可以被接受的。</span></strong></p></section><section><span leaf=""><br></span></section><p><mp-style-type data-value="10000"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/aSJsbyCHFhT0w0YjguR4bg",target="_blank" rel="noopener noreferrer">原文链接</a>
